Michele M. Luche has more than 26 years of experience in drug discovery and development, which includes programs focused specifically on Oncology, Inflammation, Infections Disease, Metabolic Disorders and CNS targeted therapeutics. Before entering into her current role, Michele held several positions of increasing responsibility at AMRI, including Technical Director, Business Development and Assistant Director, Lead Discovery Operations.
As Head of High Throughput Screening Operations at SUGEN, Inc., Michele was responsible for, among others, execution of screening programs focused on identifying modulators of protein tyrosine kinase of interest. Michele was also fortunate to be involved in development of the program leading to the marketed oncology drug SUTENT®. Following her work at SUGEN, Michele was Director of Assay Development and High Throughput Screening at CEPTYR, a company founded within ICOS Corporation in Seattle, WA. As Director, Michele was responsible for strategic development and oversight of multiple research and preclinical programs within the company in conjunction with senior leadership. Michele received training at Washington University Medical Center and St. Jude Children’s Research Hospital and has acted as consultant and project director for two companies, Accium BioSciences (Seattle, WA) and Kinetek (formerly Vancouver, BC).